Medicine composition containing erlotinib hydrochloride and preparation method of medicine composition

A technology of erlotinib hydrochloride and composition, which is applied in the field of pharmaceutical composition and preparation containing erlotinib hydrochloride, can solve problems such as flying dust, environmental pollution, and small bulk density, and achieve high process stability and dissolution Good performance and simple operation

Inactive Publication Date: 2016-03-02
SHENZHEN SALUBRIS PHARMA CO LTD
View PDF8 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Commercially available pharmaceutical silica (such as colloidal silica and micropowder silica gel) has a small bulk density, usually in the range of 0.029 to 0.042g/cm 3 Between, if sieving treatment is carried out, it is easy to cause dust to fly, causing environmental pollution, and causing damage to the health of the staff
Separate sieving treatment will also make silica aggregate into spherical shape due to electros...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition containing erlotinib hydrochloride and preparation method of medicine composition
  • Medicine composition containing erlotinib hydrochloride and preparation method of medicine composition
  • Medicine composition containing erlotinib hydrochloride and preparation method of medicine composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] type Quality (mg / tablet) parts by mass Erlotinib hydrochloride (calculated as Erlotinib) 100 1 lactose 70 0.7 microcrystalline cellulose 90 0.9 Sodium carboxymethyl starch 25 0.25 silica 10 0.1 Sodium dodecyl sulfate 3 0.03 Magnesium stearate 3 0.03

[0055] 1. Erlotinib hydrochloride and sodium lauryl sulfate are sieved for subsequent use;

[0056] 2. Mix the prescribed amount of raw materials, sodium carboxymethyl starch, and sodium lauryl sulfate for 5 minutes, add silicon dioxide and mix, and pass through a 40-mesh sieve to obtain mixed powder A;

[0057] 3. Then add the prescribed amount of lactose and microcrystalline cellulose and mix for 10 minutes to obtain the mixed powder B;

[0058] 4. Add the mixed powder B to the dry granulator for granulation, control the distance between the pressing wheels to 0.5mm, and the speed of the pressing wheels to 3r / min, to obtain a density of 1.03g / cm 3 The fl...

Embodiment 2

[0061] type Quality (mg / tablet) parts by mass Erlotinib hydrochloride (calculated as Erlotinib) 100 1 lactose 70 0.7 microcrystalline cellulose 100 1.0 Sodium carboxymethyl starch 27 0.27 silica 10 0.1 Sodium dodecyl sulfate 3 0.03 Magnesium stearate 2 0.02

[0062] 1. Erlotinib hydrochloride and sodium lauryl sulfate are sieved for subsequent use;

[0063] 2. Mix the prescribed amount of raw materials, sodium carboxymethyl starch, and sodium lauryl sulfate for 5 minutes, add silicon dioxide and mix, and pass through a 40-mesh sieve to obtain mixed powder A;

[0064] 3. Then add the prescribed amount of lactose and microcrystalline cellulose and mix for 10 minutes to obtain the mixed powder B;

[0065] 4. Add the mixed powder B to the dry granulator for granulation, control the distance between the pressing wheels to 0.5mm, and the speed of the pressing wheels to 2r / min, to obtain a density of 1.06g / cm 3 The f...

Embodiment 3

[0068] type Quality (mg / tablet) parts by mass Erlotinib hydrochloride (calculated as Erlotinib) 100 1 lactose 70 0.7 microcrystalline cellulose 100 1.0 Sodium carboxymethyl starch 25 0.25 silica 10 0.1 Sodium dodecyl sulfate 3 0.03 Magnesium stearate 2 0.02

[0069] 1. Erlotinib hydrochloride and sodium lauryl sulfate are sieved for subsequent use;

[0070] 2. Mix the prescribed amount of raw materials, sodium carboxymethyl starch, and sodium lauryl sulfate for 5 minutes, add silicon dioxide and mix, and pass through a 20-mesh sieve to obtain mixed powder A;

[0071] 3. Then add the prescribed amount of lactose and microcrystalline cellulose and mix for 10 minutes to obtain the mixed powder B;

[0072] 4. Add the mixed powder B to the dry granulator for granulation, control the spacing between the pressing wheels to 0.4mm, and the speed of the pressing wheels to 3r / min, to obtain a density of 1.18g / cm 3 The fl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Densityaaaaaaaaaa
Densityaaaaaaaaaa
Hardnessaaaaaaaaaa
Login to view more

Abstract

The invention provides a medicine composition containing erlotinib hydrochloride. The medicine composition has the advantages of being good in digestion performance, high in stability, low in clinical pharmacy risk and the like. In the production and preparation process, raw materials and auxiliary materials do not need to be specially treated, and the production process is simple.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to a pharmaceutical composition containing erlotinib hydrochloride and a preparation method. Background technique [0002] Erlotinib (CAS183321-74-6) is a small molecular compound that acts on the epidermal growth factor receptor (EGFR). EGFR is expressed on the surface of normal cells and tumor cells, and is overexpressed in specific tumor cells, especially non-small cell lung cancer (NSCLC) cells. Erlotinib can inhibit the intracellular casein related to epidermal growth factor receptor (EGFR). The phosphorylation of amino acid kinase can inhibit the growth of cancer cells by inhibiting the overexpression of EGFR in cancer cells. [0003] Erlotinib was developed by OSI Pharmaceuticals (now part of Astellas Pharmaceuticals), and its preparations were first launched in the United States in 2004 under the trade name Tarceva, which is clinically used for locally advanced or...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K31/517A61K47/38A61P35/00
Inventor 李凤陈豆
Owner SHENZHEN SALUBRIS PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap